tbuckley/cabot-search huggingface dataset:
FOLFIRI + bevacizumab as first-line treatment in advanced colorectal cancer (ACC): Final results (prot. GOIM 2601)
Authors: F. Giuliani, F. De Vita, V. Lorusso, S. Cinieri, I. Nugnes, M. Orditura, E. Maiello, S. Del Prete, S. Leo, G. Colucci
Journal: Journal of Clinical Oncology (2009)

e15007 Background: The addition of Bev to IFL obtained better OS and RR than chemotherapy alone. However IFL is not considered an optimal regimen and is certainly more toxic than FOLFIRI. To investigate the activity and efficacy of the addition of Bev to FOLFIRI, the GOIM started the following phase II study. Methods: seventy-two untreated pts with histologically/citologically confirmed diagnosis of colorectal cancer, with at least one measurable disease, age &gt; 18 yrs, PS &lt; 2 (ECOG), adequate bone marrow reserve and hepatic and renal function, with no history of cardiovascular disease, thromboembolic events or coagulative disorders and who signed informed written consent, were enrolled and received the following treatment: CPT-11 at 180 mg/m/mq on day 1, FA at 100 mg/mq as 2h infusion on days 1–2, FU at 400 mg/mq bolus on days 1–2 and FU at 600 mg/mq as 22h infusion on days 1–2 (FOLFIRI) plus Bev at 5 mg/Kg on day 1, every two weeks. A maximum of 12 cycles of chemotherapy was planned and a maintenance with Bev for 6 months was permitted. The evaluation of activity (Recist criteria) was performed every 4 cycles Results: all the enrolled pts were evaluable for activity and safety. Their main characteristics were M/F: 38/34; median PS: 0; median age 60 (range 33–73); primary site colon/rectum: 50/22 (69.4%/30.6%); main sites of disease liver: 50 (69.4%), lung: 18 (25%), lymph nodes: 19 (26.4%); synchronous/metacronous disease: 55/17 (77.7%/22.3%); multiple/single lesions: 40/32 (55.5%/44.5%).Seven (9.6%) CR, 25 (34.8%) PR, 33 (45.8%) SD and 7 PRO were observed for an ORR of 44.4% and a disease control of 90.3%. The response rate according to the main sites of disease were: liver 25/50 (50%), lung 6/18 (33.3%). The median number of administered cycle were 9 and the median TTP was 10.0 months. The main haematologic side-effects (% G3–4 NCI criteria) were: neutropenia 11%, thrombocytopenia 2.7% and anemia 4.7%, while diarrhea affected only 2.7% of pts; hypertension, thromboembolic and bleeding events were observed in 2.7%, 1.3% and 1.3% respectively. Conclusions: the addition of Bev to FOLFIRI is an active and effective first-line treatment in ACC with a good safety profile. Survival data will be presented during the meeting. No significant financial relationships to disclose.
The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.
Authors: Giuseppe Bronte, Tindara Franchina, Massimiliano Alù, Giovanni Sortino, Claudia Celesia, Francesco Passiglia, Giuseppina Savio, Agata Laudani, Alessandro Russo, Antonio Picone, Sergio Rizzo, Livio Blasi, Vincenzo Adamo, Antonio Russo
Journal: Journal of Clinical Oncology (2015)

e19030 Background: Second-line treatment for advanced non-small-cell lung cancer (aNSCLC) patients includes monotherapy with a third generation cytotoxic drug (CT) or with the tyrosine kinase inhibitor (TKI) erlotinib. These options are the actual standard treatment for EGFR gene wild-type (WT) status, as patients with EGFR mutations achieve greater benefit by the use of TKI in first-line treatment. Some prospective clinical trials and meta-analyses investigated the comparison between CT and TKI in second-line, but data are conflicting. Methods: We designed a retrospective trial to gather information about TKI sensitivity in comparison with CT. We selected from clinical records data of patients treated with at least 1 line of CT and at least 1 line of TKI. We collected information about age, sex, performance status, comorbidity, smoking status, histotype, metastatic sites, EGFR mutational status, mutation type, treatment schedule, better response and time-to-progression (TTP) for each line of treatment and overall survival (OS). Statistical analysis was performed by MedCalc version 14.12.0. Survival measures and comparisons were evaluated by Kaplan-Meier method. Results: We identified 118 patients who met the selection criteria. Mean age 64,63 (range: 32-84). M/F ratio: 73/45. EGFR non-mutated (41 WT and 54 unknown): 95. All these patients received erlotinib as second-line or third-line TKI. Median TTP at second-line: 4 (CT) vs 4 (TKI) months, p = 0,8882, HR: 1,02 (CT vs TKI), 95%CI: 0,65-1,62. Median TTP at third-line: 2 (CT) vs 3 (TKI) months, p = 0,7181, HR: 1,09 (CTvs TKI), 95%CI: 0,61-1,95. Median OS: 19 (third-line TKI) vs 15 (second-line TKI), p = 0,0946, HR: 0,68 (third-line vs second-line TKI), 95%CI: 0,43-1,06. Conclusions: This study explores the role of TKI in EGFR non-mutated aNSCLC patients. The data about the comparison of TKI with CT show no difference in TTP for both second-line and third-line treatment. The analysis of OS highlights a trend to a benefit in the group of patients who receive TKI in third-line, even if this result is not statistically significant. Further analysis are needed to find an explanation for this observation.
ZOLEDRONIC ACID INHIBITS AORTIC VALVE CALCIFICATION: A PET/CT STUDY
Authors: Andreas Synetos, Konstantinos Toutouzas, Maria Drakopoulou, Konstantinos Stathogiannis, Georgios Benetos, Iosif Koutagiar, George Agrogiannis, Eftratios Patsouris, Constantinos Anagnostopoulos, Dennis Cokkinos, Dimitris Tousoutis
Journal: Journal of the American College of Cardiology (2017)
Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma
Authors: Ao Huang, Xin Zhao, Xin-Rong Yang, Fu-Qiang Li, Xin-Lan Zhou, Kui Wu, Xin Zhang, Qi-Man Sun, Ya Cao, Hong-Mei Zhu, Xiang-Dong Wang, Huan-Ming Yang, Jian Wang, Zhao-You Tang, Yong Hou, Jia Fan, Jian Zhou
Journal: Journal of Hepatology (2017)
TRANSTHORACIC ECHOCARDIOGRAPHY TO GUIDE EXTRACORPOREAL MEMBRANE OXYGENATION DECANNULATION AFTER REFRACTORY VENTRICULAR FIBRILLATION CARDIAC ARREST TREATED WITH PRIMARY ANGIOPLASTY: A TURNDOWN PROTOCOL
Authors: Luis Felipe N. Kazmirczak, Kathleen Carlson, Jason Bartos, Cindy Martin, Ganesh Raveendran, K. Madhu, Ranjit John, Demetris Yannopoulos, Emil Missov
Journal: Journal of the American College of Cardiology (2017)
ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report.
Authors: Kalai Khadija, Nathalie Auger, Beranger Lueza, Frederic Commo, Alexander Valent, Vanessa Rousseau, Nicolas Dorvault, Luc Friboulet, Ken Olaussen, Laetitia Rajpar, David Planchard, Ludovic Lacroix, Jean-Pierre Pignon, Jean-Charles Soria, Benjamin Besse
Journal: Journal of Clinical Oncology (2012)

10556 Background: ALK high copy number (HCN) seems to be a frequent event, described in 13-17% of Non-small cell lung cancer (NSCLC). The goal of this study was to describe ALK genomic aberrations on NSCLC patients and cell lines, to explore the ALK HCN response to crizotinib through in vitro assays and to report three patients case. Methods: 191 Paraffin embedded specimens from advanced NSCLC patients and 27 NSCLC cancer cell lines were screened for ALK copy number by fluorescent in situ hybridization (FISH). Crizotinib sensitivity was evaluated in 9 cell lines through WST1 assays and clonogenic tests. Three patients exhibiting ALK HCN were assessed for response to crizotinib. Results: EML4-ALK translocation was present in 22 pts (11.5%). 21 pts (11%) exhibited over 6 copies of ALK. 6 (22%) cell lines displayed more than 5 copies of ALK, 19 (70%) presented a gain of 3 or 4 ALK copy number, only one cell line exhibited normal ALK copies and one harbored EML4-ALK translocation. FISH with CEP2 revealed a polysomy of chromosome 2 in cases with ALK HCN.Out of the 9 cell lines tested, 4 ALK HCN cell lines (H661, A427, BEN, H1299) exhibited increased sensitivity for crizotinib vs. 3 low ALK copy number (LCN) cell lines (H1975, H1651, H1650) with a low sensitivity. Median IC50 with crizotinib values was1750 nM [300-2800nM] in ALK HCN cell lines vs 4500 nM [800-8000nM] in ALK LCN cell lines, p=0.35. 3 patients with ALK HCN tumor received crizotinib ( in 4th , 5th and 6th -line therapy) for 2, 3 and 5 months with stable disease as best response and clinical benefit in 2 pts. Conclusions: ALK HCN may predict sensitivity to crizotinib. A clinical study is planned in ALK HCN pts.
STRUT PROTRUSION DISTANCE AND SHAPE IMPACT ON ENDOTHELIAL SHEAR STRESS: INSIGHTS FROM PRE-CLINICAL STUDY COMPARING MIRAGE AND ABSORB BIORESORBABLE SCAFFOLDS IN PORCINE CORONARY MODEL
Authors: Erhan Tenekecioglu, Yohei Sotomi, Ryo Torii, Christos Bourantas, Yosuke Miyazaki, Solomon Su, Yoshinobu Onuma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2017)
Deletion of PAX5 Is Frequently Accompanied by CDKN2A Deletion but Not by ETV6-RUNX1 Rearrangement In B-Lineage Acute Lymphoblastic Leukemia
Authors: Miyoung Kim, Young Jin Jeon, Cha Ja She, Sang Mee Hwang, Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn, Sung-Soo Yoon, Byoung Kook Kim, Myoung Hee Park, Dong Soon Lee
Journal: Blood (2010)
Triticum vulgare mouthwashes (TVM) for patients (pts) with oral mucositis (OM) induced by chemotherapy and chemoradiotherapy (ONCOLGroup study)
Authors: E. Carrasco-Chaumel, A. F. Cardona, E. G. Ospina, L. M. Montaño, R. Noemí, M. Bleda, H. Carranza, C. Vargas, J. M. Otero, C. Castro
Journal: Journal of Clinical Oncology (2009)

e20570 Background: OM is a frequent complication of cancer therapy in Colombia. Triticum vulgare has been reported to effectively treat mucosal and skin disturbances. Methods: To evaluate the safety and efficacy of TVM for the control of OM induced by chemoradiotherapy in pts with head and neck cancer (HNC) and by chemotherapy in pts with haematological malignancies (HM). Thirty-one pts received TVM delivered in a spray four times daily to the whole oral cavity until the OM being resolved. The primary endpoint was the OM grade evaluated daily using the Nebraska scale (NS). Secondary endpoints were OM duration, weight loss, pain and TVM tolerance; the latter two were evaluated using a visual analogue scale (VAS). Results were compared with data from 42 pts with OM treated with saline mouthwashes (SM) in a previous clinical trial. Results: Nineteen pts had HM and 12 had HNC; those with HM developed OM on day 9 of chemotherapy (range, 7–14), whilst those having HNC did so towards day 17 of chemoradiation (range, 13–26). Using NS 38% of pts developed GI OM, 46% GII OM and 16% GIII OM. Moderate and severe OM occurred more frequently amongst HNC pts (8 vs 1, p = 0.047), mean OM duration in HNC pts was 12±4.5 days, whilst it was 7 ±3 days (p = 0.047) in pts with HM. Median OM duration in pts treated with TVM was 5.4 days (range, 2–9) vs 7 days (range 1–17) for pts treated with SM (p = 0.048). TVM appears to reduce weight loss, especially in pts with HNC (p = 0.058); however, no changes were documented regarding saliva characteristics and production, mucosal bleeding and voice properties. Evaluation of pain did not reveal differences between the groups (VAS 5.5 for the TV compared to VAS 6.2 for SM; p = 0.27) but the proportion of pts suffering from pain VAS≥7 differed between both populations (8% TV vs 23% SM; p = 0.043). There are no significant adverse events with TVM. Conclusions: TVM is safe and has therapeutic activity against OM. Further phase III study is needed to confirm these results. No significant financial relationships to disclose.
NOT ALL SHOCKS ARE CREATED EQUAL: ACUTE CORONARY SYNDROME IN THE SETTING OF PANHYPOPITUITARISM
Authors: Dharmaraj Karthikesan, Huan Yean Kang, Kai Soon Liew, Ahmad Shukri Saad, Wan Faizal Wan Rahimi Shah, Gerard Jason Mathews, Ahmad Faiz Mohd Ezanee, Yi Zhi Cheng, Azrina Abdul Kadir, Kantha Rao Narasamuloo, Abdul Syukur Abdullah, Nor Shaffinaz Yusoff Azmi, Omar Ismail, Chee Tat Liew, Saravanan Krishinan
Journal: Journal of the American College of Cardiology (2017)
Molecular pattern of breast cancer among a series of Egyptian patients.
Authors: Salah Eldeen Elmesidy, Wessam Elsherief, Mohamed Abdelshafy, Walid Hammam
Journal: Journal of Clinical Oncology (2013)

e11614 Background: Triple negative (TN) breast cancer has a bad prognosis. It is associated with a poor progression-free and overall survivals. Accordingly, we explored the outcome of different molecular subtypes among a series of Egyptian breast cancer patients. Methods: A total of 661 non-metastatic breast cancer patients' files with were reviewed from Kasr Al-Aini Center of Clinical Oncology and Nuclear Medicine of Cairo University between January 2005 and December 2010. Data were analyzed for age; menopausal status, tumour size, nodal status, pathological type, grade; estrogen status, progesterone status, and human epidermal growth factor receptor 2 (HER2) status. Disease free survival (DFS) was the primary end point. Results: The median age was 50 years. 50.4% of patients were premenopausal, 93.1% had invasive duct carcinoma, 93.3% had grade II tumours, 79.4% had early tumours (T1&amp;T2), 70.4% had positive lymph nodes, 51.7% had luminal A subtype, 21.3% had luminal B, 10.2% had HER2-enriched and 16.6% had TN. Disease free survival after 3 years for each subtype was 87.8% for luminal A, 86% for luminal B, 69% for TN and 66% for HER2 (p= .008). The 3-year disease-free survival was significantly better for postmenopausal patients 92.1% as compared with premenopausal patients 80.1% (P= &lt;0.001), with early tumours (T1&amp;T2) 92.1% &amp; 87.3% respectively as compared with advanced tumours (T3+T4) 80.1% (p= &lt;0.001), LN negative (N0) 98.1% as compared with LN positive (N1+N2) 85.2% and (N3) 68% (p= &lt;0.001), (ER) positive 90.2% as compared with (ER) negative 78.2% (p= &lt;0.001), (PR) positive 90% as compared with (PR) negative 80.2% (p= 0.003), non TNBC 89.8% as compared with TN 72.1% (p= 0.012). The 3-year disease-free survival for TN patients who received adjuvant platinum-based chemotherapy was 46% and for those who received adjuvant non-platinum chemotherapy was 78% (p= 0.135). Conclusions: In our series of Egyptian patients luminal breast cancer subtypes (A and B) had the highest 3-year disease-free survival followed by TN then HER2-enriched type. Adjuvant platinum based chemotherapy had no impact on the 3-year disease-free survival when compared with non-platinum chemotherapy in TN patients.
Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,
Authors: Ana Paula Alencar de Lima Lange, Ana Sílvia Gouvea Lima, Rafael Henriques Jacomo, Raul AM Melo, Rosane Bittencourt, Ricardo Pasquini, Katia B. Pagnano, Evandro Fagundes, Maria de Lourdes L. F. Chauffaille, Carlos S Chiattone, Robert E. Gallagher, Bob Lowenberg, Raul Ribeiro, Francesco Lo-Coco, David Grimwade, Miguel A. Sanz, Eduardo M. Rego
Journal: Blood (2011)
COMPARISON OF IN VIVO OPTICAL COHERENCE TOMOGRAPHY DERIVED PLAQUE PHENOTYPE AND BURDEN WITH HISTOLOGY IN A PORCINE MODEL OF ADVANCED CORONARY ATHEROSCLEROSIS
Authors: Christian Bo Poulsen, Ryan Pedrigi, Niels Holm, Nilesh Pareek, Ismail Kilic, Anouk L. Post, Carlo Di Mario, Jacob Bentzon, Hans Botker, Erling Falk, Rob Krams, Ranil de Silva
Journal: Journal of the American College of Cardiology (2017)
Hematopoeitic Stem Cells and Their Progenitors Critically Require Autophagy to Promote Early Engraftment Following Allogeneic Stem Cell Transplantation
Authors: Katie E Lineburg, Lucie Leveque-El Mouttie, Laetitia Le Texier, Bianca Teal, Rachel D Kuns, Geoffrey R Hill, Kelli P A MacDonald
Journal: Blood (2015)
IMBALANCE BETWEEN E-NOS AND MRP4 GENE EXPRESSION IN TYPE 2 DIABETES MELLITUS MAY EXPLAIN THE HIGHER RISK OF NSTEMI IN DIABETIC SUBJECTS
Authors: Luigi M. Biasucci, Giulio La Rosa, Claudia Mandolini, Maria Chiara Grimaldi, Filippo Crea
Journal: Journal of the American College of Cardiology (2017)
A CROSS COMPARISON STUDY OF RIGHT VENTRICULAR HYPERTROPHY WITH ELECTROCARDIOGRAPHY AND CARDIAC MAGNETIC RESONANCE IN PATIENTS WITH PULMONARY HYPERTENSION
Authors: Matthew S. Tong, Jose R. Po, Talha Meeran, Mark Doyle, Geetha Rayarao, Robert Biederman
Journal: Journal of the American College of Cardiology (2017)
Vulvar melanoma: A monocentric retrospective study on 29 cases.
Authors: Giulio Tosti, Edoardo Botteri, Giuseppe Spadola, Federica Baldini, Massimo Mosconi, Pier Francesco Ferrucci, Sara Gandini, Elisabetta Pennacchioli, M. Giulia Zampino, Emilia Cocorocchio, Francesco Verrecchia, Francesco Cataldo, Rosana Buffon, Mario Sideri, Angelo Maggioni, Alessandro Testori
Journal: Journal of Clinical Oncology (2012)

e19036 Background: Vulvar melanoma (VM) represents 3-7% of melanoma in women. The 5-year survival rate ranges from 8 to 55%. Surgical excision represents the best definitive therapy but surgical radicality does not impact on recurrence or survival. Methods: Thirty women with histologically confirmed VM diagnosed between 1993 and 2009 were selected for this monocentric retrospective study. One patient with metastases at time of diagnosis was excluded from the statistical analysis. Clinical, pathological and follow-up data were collected. Cumulative incidences of events were calculated and compared across subgroups by means of the Gray test. Results: Average age at diagnosis was 62 years. Average Breslow thickness was 4.91 mm. Ulceration was present in 11 cases and was unknown in 5. One case of VM was multifocal at presentation. Eleven patients underwent a wide local excision, 11 a hemivulvectomy and 7 a radical vulvectomy Sentinel node biopsy was performed in 23 patients and at least one positive sentinel node was found in 8 cases. Eight patients received adjuvant therapy. Ten patients had a second tumor (other than melanoma); of these, a breast cancer was recorded in 5 cases. Four patients had a second primary melanoma: of the vulva (n=2), vagina (n=1), and urethra (n=1). Median follow-up among ongoing survivors was 79 months and median overall survival was 69 months. The 5-year overall survival was 55.4%. Median event free survival 34 months. Positive lymph nodal status was associated with an increased risk of loco-regional recurrences (P=0.04). Positive lymph nodal status (P=0.06), Breslow thickness &gt; 2mm (P=0.05) and number of mitoses &gt; 10/mm2 (P=0.04) increased the risk of distant metastases. Age, ulceration and type of surgery were not significantly associated with any type of event. Conclusions: Lymph node involvement, elevated depth of invasion and a high number of mitoses were the most important prognostic factors for locoregional recurrence and distant metastases. The same trends were observed for the overall survival, but results were not statistically significant. Conservative surgery in the form of wide local excision with adequate margins may replace vulvectomy. Sentinel node biopsy is feasible and its role in VM should be further investigated.
Randomized phase IV trial of oral tegafur and low dose leucovorin versus intravenous 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer (ACC): Final results
Authors: A. Salud, E. Saigi, E. Batiste-Alentorn, F. Losa, L. Cirera, M. Mendez, J. M. Campos, A. Galan, M. P. Escudero, M. Nogue
Journal: Journal of Clinical Oncology (2004)

3547 Background: In a previous phase II trial in ACC, an all-oral regimen of Tegafur and Leucovorin obtained an overall response rate of 30% (Cancer,1998;83:254–8). We conducted a multicenter randomized equivalence trial in patients with ACC, to compare oral Tegafur (FT) + Leucovorin (LV) with the Mayo schedule. Methods: Patients with locally advanced or metastatic colorectal adenocarcinoma who were not candidates for radical therapy, were randomly assigned to treatment if they had KPS ≥ 60%, measurable or evaluable disease, adequate bone marrow, liver and renal function, and normal oral intake. Arm 1: LV (20 mg/m2 intravenous) followed by 5FU (425 mg/m2 intravenous) daily for 5 days every 4 weeks for 3 cycles then every 5 weeks. Arm 2: oral FT (750 mg/m2 daily for 21 days) and oral LV (15 mg/m2 every 8 hours) every 28 days. Treatment was maintained until disease progression or toxicity. Primary end points were objective response (OR) and overall survival (OS). Secondary objectives included time to progression (TTP), toxicity and QOL. Results: 237 (123 Arm 1, 114 Arm 2) of the 290 planned patients from 16 centers were randomized and evaluated. Patient characteristics were well balanced between the two arms. OR and OS rates are summarized in the table. Median TTP in Arms 1 and 2 was 189 (95% CI: 166–212) and 181 days (95% CI: 163–199), respectively. Grade III/IV toxicities were neutropenia (4.1 vs. 0%) asthenia (5% vs. 10.5%), diarrhea (14% vs. 18.4%), stomatitis (7.4 vs. 6.1%), nausea (0.8% vs. 3.5%) and vomiting (2.5% vs. 4.4%). Delays and dose reductions were more frequent in Arm 2. Conclusions: The results show that FT+LV was comparable to 5-FU on all primary and secondary study endpoints, making it a valid alternative to the 5-FU intravenous schedule in these patients. Oral Tegafur should be tested in combination with other treatments . No significant financial relationships to disclose.
Velcade®, Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial
Authors: HyeonSeok Eom, Yeo-Kyeoung Kim, Joo-Seop Chung, Kihyun Kim, Hyo-Jung Kim, HoYoung Kim, Jong-Youl Jin, Young-Rok Do, Suk-Joong Oh, Cheolwon Suh, Chu-Myong Seong, Chul Soo Kim, Dong Soon Lee, Jae Hoon Lee
Journal: Blood (2008)
Erratum: Expression and mutation status of candidate kinases in multiple myeloma
Authors: J O Claudio, F Zhan, L Zhuang, R Khaja, Y X Zhu, K Sivananthan, S Trudel, E Masih-Khan, R Fonseca, P L Bergsagel, S W Scherer, J Shaughnessy, A K Stewart
Journal: Leukemia (2008)
Refractory Thrombocytopenia Due to Allo-Immune Anti-CD36 Complicating Unrelated Donor Bone Marrow Transplant in a CD36-Negative Recipient.
Authors: William R. Broderick, Amir A. Toor, Brian R. Curtis, Tulio E. Rodriguez, Scott E. Smith, Patrick J. Stiff, Phillip J. DeChristopher
Journal: Blood (2007)
CLINICAL OUTCOMES ASSOCIATED WITH IMPELLA VERSUS IABP USE IN STABLE PATIENTS UNDERGOING HIGH RISK PERCUTANEOUS CORONARY INTERVENTION
Authors: Sabato Sorrentino, Usman Baber, Jaya Chandrasekhar, Serdar Farhan, Michela Faggioni, Birgit Vogel, Samantha Sartori, Jason Kovacic, Pedro Moreno, Javed Suleman, Pooja Vijay, Gennaro Giustino, George Dangas, Roxana Mehran, Annapoorna Kini, Samin Sharma
Journal: Journal of the American College of Cardiology (2017)
Excellent Disease-Free Survival after Double Cord Blood Transplantation Using a Reduced Intensity Chemotherapy Only Conditioning Regimen in a Diverse Adult Population.
Authors: Karen K. Ballen, Thomas R. Spitzer, Beow Yeap, McAfee Steve, Bimalanghsu R. Dey, Eyal Attar, Edwin Alyea, Corey Cutler, Vincent Ho, Stephanie Lee, Robert Soiffer, Joseph H. Antin
Journal: Blood (2005)